RenovoRx, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RNXT research report →
About the company
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination.
- CEO
- Shaun R. Bagai
- IPO
- 2021
- Employees
- 10
- HQ
- Mountain View, CA, US
Price Chart
- Market Cap
- $34.25M
- P/E
- -2.74
- P/S
- 23.00
- P/B
- 3.11
- EV/EBITDA
- -1.80
- Div Yield
- 0.00%
- Gross Margin
- 78.71%
- Op Margin
- -864.34%
- Net Margin
- -823.98%
- ROE
- -138.61%
- ROIC
- -105.91%
- Revenue
- $1.12M · 2511.63%
- Net Income
- $-11,168,000 · -26.71%
- EPS
- $-0.32 · 13.51%
- Op Income
- $-12,510,000
- FCF YoY
- -20.12%
- 52W High
- $1.45
- 52W Low
- $0.70
- 50D MA
- $0.89
- 200D MA
- $0.97
- Beta
- 0.99
- Avg Volume
- 292.61K
Get TickerSpark's AI analysis on RNXT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 22, 22 | RYAN UNA S | other | 16,206 |
| Apr 22, 22 | RYAN UNA S | other | 26,838 |
| Mar 3, 22 | RYAN UNA S | other | 6,332 |
| Mar 3, 22 | RYAN UNA S | other | 47,789 |
| May 19, 26 | VOLL MARK | buy | 25,000 |
| Apr 3, 26 | Bagai Shaun | other | 946,107 |
| Apr 3, 26 | VOLL MARK | other | 80,000 |
| Apr 3, 26 | Gentry Leesa | other | 128,550 |
| Apr 3, 26 | Agah Ramtin | other | 621,727 |
| Mar 25, 26 | VOLL MARK | other | 12,380 |
Our RNXT coverage
Recent articles, reports, and earnings notes.
No research on RNXT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RNXT report →Similar companies
Peers in the same neighborhood.